Mitral-Valve Repair versus Replacement for Severe Ischemic Mitral Regurgitation

251 pts with severe ischemic MR were randomized to MV repair or chordal-sparing MV replacement.  The end point was LVESVI at 12 mos.  LVESVI and mortality were similar between the groups at follow-up.  Recurrent MR was more common in the repair group (32.6% vs 2.3%).  Other outcomes including major adverse events and QOL were similar between the groups.